| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1From the University Eye Hospital Vienna, Vienna, Austria; and the 2University Eye Hospital Schleswig-Hostein, Lübeck, Germany.
PURPOSE. To improve selectivity of verteporfin therapy (PDT) in neovascular age-related macular degeneration (AMD) using modified treatment parameters.
METHODS. Nineteen consecutive patients with predominantly classic choroidal neovascularization (CNV) in AMD were treated with 6 mg/m2 verteporfin given as bolus infusion. Patients received PDT with a fluence of either 25 or 50 J/cm2. Choroidal perfusion changes were evaluated by indocyanine green angiography (ICGA) at baseline, day 1, week 1, week 4, and month 3. Secondary outcomes were CNV closure rate and therapy-induced leakage documented by fluorescein angiography (FA). The safety of the treatment was assessed with ETDRS visual acuity.
RESULTS. Complete CNV closure was achieved in all patients at day 1. Choroidal hypoperfusion was minimal in eyes treated with a reduced fluence of 25 J/cm2. Most patients treated with 50 J/cm2 showed significant choriocapillary nonperfusion at week 1, lasting as long as 3 months. A transient PDT-induced increase in leakage area in FA at day 1 was found to be more extensive in the 50-J/cm2 group.
CONCLUSIONS. Bolus administration of verteporfin combined with a reduced light dose achieved improved selectivity of photodynamic effects, avoiding collateral alteration of the physiologic choroid while obtaining complete CNV closure. An increased selectivity with decreased effect on the surrounding choroid should be of advantage in verteporfin monotherapy as well as in combination strategies.
This article has been cited by other articles:
|
|
 |
|
  C G Kiss, C Simader, S Michels, and U Schmidt-Erfurth Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study Br. J. Ophthalmol., December 1, 2008; 92(12): 1620 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Sacu, A Varga, S Michels, G Weigert, K Polak, P V Vecsei-Marlovits, and U Schmidt-Erfurth Reduced fluence versus standard photodynamic therapy in combination with intravitreal triamcinolone: short-term results of a randomised study Br. J. Ophthalmol., October 1, 2008; 92(10): 1347 - 1351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Weigert, S Michels, S Sacu, A Varga, F Prager, W Geitzenauer, and U Schmidt-Erfurth Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study Br. J. Ophthalmol., March 1, 2008; 92(3): 356 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tanito, S. Kaidzu, and R. E. Anderson Delayed Loss of Cone and Remaining Rod Photoreceptor Cells due to Impairment of Choroidal Circulation after Acute Light Exposure in Rats Invest. Ophthalmol. Vis. Sci., April 1, 2007; 48(4): 1864 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tatar, K. Shinoda, A. Adam, T. Eckert, C. Eckardt, K. Lucke, C. Deuter, K. U. Bartz-Schmidt, and S. Grisanti Effect of verteporfin photodynamic therapy on endostatin and angiogenesis in human choroidal neovascular membranes Br. J. Ophthalmol., February 1, 2007; 91(2): 166 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Kozak, L Cheng, D E Cochran, and W R Freeman Phase I clinical trial results of verteporfin enhanced feeder vessel therapy in subfoveal choroidal neovascularisation in age related macular degeneration Br. J. Ophthalmol., September 1, 2006; 90(9): 1152 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M Stewart Half dose verteporfin PDT for central serous chorioretinopathy Br. J. Ophthalmol., July 1, 2006; 90(7): 805 - 806. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
